Biophore applies for DCGI approval for emergency use of Aviptadil to treat COVID-19

Biophore India Pharmaceuticals has announced that it has applied for DCGI emergency use approval of Aviptadil Inhalation for marketing in India to treat moderate to severe cases of COVID-19. Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.

A company statement informed, “Aviptadil is a synthetic form of Vasoactive Intestinal Peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. These observations are based on results of multiple trials of Aviptadil against COVID-19 globally in patients with respiratory failure and the same have been submitted to DCGI for their review.”

Dr Jagadeesh Babu Rangisetty, CEO, Biophore, said, “Biophore has developed this highly complex peptide in a very short period of time, primarily due to the extensive focus of the company in prioritising COVID related products over the last one year. Aviptadil is a very promising treatment option for COVID, especially in severe hospitalised cases where trials have shown a high recovery percentage and we hope to be able to quickly make it available through this approval.”

Biophore had also received approval for Favipiravir, in India during the first wave and is a key manufacturer of Sulfobutyl Ether beta Cyclodextrin (SBECD), a key excipient in the manufacturing of Remdesivir Injections.